Porter A, Barcelon J M, Budker R L, Marsh L, Moriarty J M, Aguiar X, Rao J, Ghorani E, Kaur B, Maher G, Seckl M J, Konecny G E, Cohen J G
University of California Los Angeles, Division of Hematology Oncology, Los Angeles, CA, USA.
University of California Los Angeles, Division of Gynecologic Oncology, Los Angeles, CA, USA.
Gynecol Oncol Rep. 2021 May 7;36:100782. doi: 10.1016/j.gore.2021.100782. eCollection 2021 May.
Placental Site Trophoblastic Tumor (PSTT) is a rare malignancy that often presents with extensive disease and can be resistant to traditional treatments. We present the case of a woman with stage IV PSTT who was initially managed with neoadjuvant chemotherapy followed by tumor debulking. Adjuvant therapy was guided by further pathologic analysis that revealed high levels of staining for PD-L1 as well as the presence of tumor infiltrating lymphocytes (TILs). Subsequently, the patient was treated with traditional chemotherapy with the EP/EMA regimen with the addition of pembrolizumab. The patient's treatment course was complicated by the development of pulmonary arteriovenous malformations, autoimmune thyroiditis thought to be secondary to immunotherapy, and significant tinnitus secondary to platinum agents. Currently the patient is in follow up and remains in a complete remission.
胎盘部位滋养细胞肿瘤(PSTT)是一种罕见的恶性肿瘤,常表现为广泛病变,且可能对传统治疗耐药。我们报告一例IV期PSTT患者,最初接受新辅助化疗,随后进行肿瘤减瘤手术。辅助治疗依据进一步的病理分析进行,该分析显示程序性死亡受体配体1(PD-L1)染色水平高以及存在肿瘤浸润淋巴细胞(TILs)。随后,患者接受了含EP/EMA方案的传统化疗并加用帕博利珠单抗。患者的治疗过程因出现肺动静脉畸形、被认为继发于免疫治疗的自身免疫性甲状腺炎以及铂类药物导致的严重耳鸣而变得复杂。目前患者正在随访中,仍处于完全缓解状态。